[1]郑 琳,陈 果,李黎博.BD和BAD化疗方案治疗多发性骨髓瘤的疗效比较[J].郑州大学学报(医学版),2019,(03):435-438.[doi:10.13705/j.issn.1671-6825.2018.06.123]
 ZHENG Lin,CHEN Guo,LI Libo.Efficacy of BD and BAD chemotherapy regimens for multiple myeloma[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(03):435-438.[doi:10.13705/j.issn.1671-6825.2018.06.123]
点击复制

BD和BAD化疗方案治疗多发性骨髓瘤的疗效比较()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年03期
页码:
435-438
栏目:
应用研究
出版日期:
2019-05-20

文章信息/Info

Title:
Efficacy of BD and BAD chemotherapy regimens for multiple myeloma
作者:
郑 琳陈 果李黎博
成都市第三人民医院血液科 成都 610031
Author(s):
ZHENG Lin CHEN Guo LI Libo
Department of Hematology,the Third People's Hospital of Chengdu, Chengdu 610031
关键词:
BD方案 BAD方案 多发性骨髓瘤 肾功能
Keywords:
BD chemotherapy regimen BAD chemotherapy regimen multiple myeloma renal function
分类号:
R733.3
DOI:
10.13705/j.issn.1671-6825.2018.06.123
摘要:
目的:分析BD(硼替佐米+地塞米松)、BAD(硼替佐米+地塞米松+阿霉素)化疗方案治疗多发性骨髓瘤(MM)的疗效。方法:MM患者90例,采用BD、BAD方案化疗各45例,均治疗4个疗程后评估疗效,比较两组化疗前后血清胱抑素C(Cys-C)、尿素(Urea)、肌酐(Scr)、β2-微球蛋白(β2-MG)水平及骨髓瘤细胞比例,比较两组不良反应发生率和复发率。结果:BAD组总有效率93.3%,高于BD组的73.3%(P<0.05)。BAD组、BD组不良反应发生率分别为28.9%、22.2%,复发率分别为8.9%、13.3%,差异均无统计学意义(P>0.05)。化疗后两组血清Cys-C、Urea、Scr、β2-MG及骨髓瘤细胞比例均较治疗前下降,且BAD组下降幅度大于BD组(P<0.05)。结论:BD、BAD化疗方案对MM均有一定疗效,BAD方案优于BD方案。
Abstract:
Aim:To analyze the efficacy of BD(bortezomib plus dexamethasone)and BAD(bortezomib plus dexamethasone plus adriamycin)chemotherapy regimens for multiple myeloma(MM).Methods:A total of 90 patients with MM were randomly allocated into two groups, 45 cases received BD chemotherapy regimen(BD group),and the other 45 cases received BAD chemotherapy for 4 courses of treatment. The levels of serum Cystatin C(Cys-C), Urea, creatinine(Scr),β2-microglobulin(β2-MG),and the proportion of myeloma cells were detected before and after chemotherapy. The incidence of adverse reactions and recurrence rate were recorded.Results:The total effective rate of BAD group was 93.3%,higher than that(73.3%)of BD group(P<0.05). The incidence of adverse reactions of BAD and BD groups was 28.9%,22.2%,recurrence rate was 8.9%,13.3%,respectively,and there was no significant differences between the two groups(P>0.05).The levels of serum Cys-C, Urea, Scr,β2-MG and the proportion of myeloma cells after chemotherapy in both groups were decreased compared with those before chemotherapy,especially in BAD group(P<0.05).Conclusion:Both BD and BAD chemotherapy regimens are effective for MM treatment,and BAD regimen may be superior.

参考文献/References:

[1] LEE H,KONG SY,SOHN JY,et al.Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma[J].Biomed Res Int,2014(4):145619
[2] 戴豫苏,孙玲,孙慧,等.硼替佐米联合地塞米松及沙利度胺治疗多发性骨髓瘤的临床疗效[J].郑州大学学报(医学版),2016,51(4):554
[3] 韦慧萍,兰访,朱璇,等.相关实验室检查指标与多发性骨髓瘤合并肾损害的关系研究[J].广西医科大学学报,2016,33(6):996
[4] 王丽.Scr检测在急性肾小球肾炎早期肾损伤评估中的意义[J].标记免疫分析与临床,2017,24(4):422
[5] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志,2015,54(12):1066
[6] Anonymous.NCCN clinical practice guidelines in oncology[EB/OL].http://www.nccn.org.2009.
[7] RÖLLIG C,KNWOP S,BORNHÄUSER M.Muitiple myeloma[J].Lancet,2015,385(9983):2197
[8] ALMUEILO SH.Renal failure in patients with multiple myeloma[J].Saudi J Kidney Dis Transpl,2015,26(3):482
[9] 沈静,刘卓刚,杨威.硼替佐米联合不同化疗药物治疗多发性骨髓瘤疗效和安全性的Meta分析[J].现代肿瘤医学,2016,24(21):3469
[10]朱蓓英.硼替佐米为基础的联合化疗方案及细胞遗传学特性与多发性骨髓瘤治疗反应及预后的回顾性研究[D].杭州:浙江大学,2015.
[11]徐昕,徐茂忠,戴秋新,等.两种治疗方案对老年多发性骨髓瘤的临床疗效[J].医学与哲学,2016,37(4):27
[12]孙玲玲,孟艳力,宋广玉,等.血清胱抑素C对多发性骨髓瘤肾损害的早期评估[J].中国医师进修杂志,2014,37(25):56
[13]王珂.含硼替佐米的不同联合化疗方案治疗初诊多发性骨髓瘤的临床分析[D].郑州:郑州大学,2016.
[14]刘延方,周阳,孙慧,等.含硼替佐米方案治疗POEMS综合征4例[J].郑州大学学报(医学版),2016,51(3):426

备注/Memo

备注/Memo:
【基金项目】四川省医学会基金项目(Q150116)
【作者简介】郑琳,女,1967年6月生,本科,副主任医师,研究方向:骨髓增生异常综合征及多发性骨髓瘤、恶性淋巴瘤、急慢性白血病等血液肿瘤的诊治,E-mail:9497456@qq.com
更新日期/Last Update: 2019-05-20